NEWS & EVENTS

Inotrem and the Crohn’s & Colitis Foundation sign a R&D collaboration agreement to support the development of a new therapeutic approach in Inflammatory Bowel Disease (IBD)

Paris (France), April 14th 2022. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD. The Crohn’s & Colitis Foundation is one of world’s largest and most influential non-profit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis.

Read full article (PDF)